A Phase I Study of CYT107 (Recombinant Glycosylated Human IL-7) [interleukin-7] in Recipients of HLA Matched Ex Vivo T Cell Depleted Bone Marrow or Peripheral Blood Stem Cell Transplant

Trial Profile

A Phase I Study of CYT107 (Recombinant Glycosylated Human IL-7) [interleukin-7] in Recipients of HLA Matched Ex Vivo T Cell Depleted Bone Marrow or Peripheral Blood Stem Cell Transplant

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jul 2012

At a glance

  • Drugs Interleukin-7 (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Jul 2012 Actual end date (Apr 2011) added as reported by ClinicalTrials.gov.
    • 08 Dec 2010 Results presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH-2010), and topline results reported in a Cytheris media release.
    • 11 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top